The main objective of the Primate Core is to provide NCCFAR investigators the ability to conduct pilot primate studies designed to gather preliminary data for a NIH grant submission and increase collaboration with non-primate researchers involved in AIDS research. Pilot projects will be solicited by the Developmental Core, reviewed by the Scientific Review Committee and recommended for funding. The costs for the primate use in the approved pilot projects will be covered by the budget of Primate Core. In addition, the resources of the Primate Core may be used to support supplemental studies that are related to NIH funded active grants to investigators at University of California, Davis (UC Davis), Viral and Rickettisial Disease Laboratory/California Department of Health Services (VRDL/CDHS) at Berkeley and the University of California Berkeley (UC Berkeley). The Primate Core will support studies that are designed to perform proof of concept experiments and to test hypotheses based on clinical observations in HIV-infected patients, or to conduct initial testing of specific antiviral intervention strategies. Studies of antiviral therapy and vaccine development will be especially appropriate for testing in the Simian Immunodeficiency Virus (SIV) and Simian-human Immunodeficiency Virus (SHIV)-infected rhesus macaque models available through the Primate Core. The Primate Core will provide a vehicle to conduct preclinical studies in monkeys that are coordinated with planned, or ongoing, studies conducted by basic and clinical NCCFAR investigators. Thus, the NCCFAR, and the Primate Core, will provide investigators with the translational research opportunities that have been missing at the participating institutions of NCCFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI049366-02
Application #
6654023
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-09-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Sena, Angela A S; Glavan, Tiffany; Jiang, Guochun et al. (2016) Divergent Annexin A1 expression in periphery and gut is associated with systemic immune activation and impaired gut immune response during SIV infection. Sci Rep 6:31157
Dubie, Robert A; Maksaereekul, Saipiroon; Shacklett, Barbara L et al. (2009) Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386:109-21
Asmuth, D M; Abel, K; George, M D et al. (2008) Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques. J Med Primatol 37:26-30
George, M D; Verhoeven, D; McBride, Z et al. (2006) Gene expression profiling of gut mucosa and mesenteric lymph nodes in simian immunodeficiency virus-infected macaques with divergent disease course. J Med Primatol 35:261-9
Kuekrek, Haydar; Schlingmann, Tobias; Valdez, Hernan et al. (2005) Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS 19:1967-74
Israel-Ballard, Kiersten; Chantry, Caroline; Dewey, Kathryn et al. (2005) Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study. J Acquir Immune Defic Syndr 40:175-81
Sankaran, Sumathi; Guadalupe, Moraima; Reay, Elizabeth et al. (2005) Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A 102:9860-5
George, Michael D; Reay, Elizabeth; Sankaran, Sumathi et al. (2005) Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79:2709-19